Table: Adverse reactions reported by 5% or more of adolescents (ages 13-17 years) taking Mydayis and that were at least twice the incidence in patients taking placebo in a 4-week clinical trial.1
*Adverse reactions leading to discontinuation: dizziness, depression,abdominal pain upper, and viral infection.
Safety data is from 1 controlled trial (dose-optimization study) with 78 adolescent patients exposed to doses of 12.5 mg - 25 mg of Mydayis.1,2
Most events of insomnia, weight decrease, and decreased appetite occurred early.2,3
In adult patients (18 to 55 years) with ADHD, the most common adverse reactions (incidence ≥5% and at a rate at least twice placebo) were insomnia (31% Mydayis n=626, 8% placebo n=328), decreased appetite (30%, 4%), dry mouth (23%, 4%), decreased weight (9%, 0%), increased heart rate (9%, 0%), and anxiety (7%, 3%).1
In a controlled trial including adolescent patients (ages 13 to 17 years), 5% (4/78) of Mydayis-treated patients discontinued due to adverse reactions compared to 0% (0/79) of placebo-treated patients. The most frequent adverse reaction leading to discontinuation (i.e., leading to discontinuation in at least 1% of Mydayis-treated patients and at a rate at least twice that of placebo) were dizziness (1%, n=1), depression (1%, n=1), and abdominal pain upper (1%, n=1), and viral infection (1%, n=1).
In the controlled trials of adult patients aged 18 to 55 years, 9% of Mydayis-treated patients discontinued due to adverse reactions, compared to 2% of placebo-treated patients. The most frequent adverse reactions leading to discontinuation in adult patients (i.e., leading to discontinuation in at least 1% of Mydayis-treated patients and at a rate at least twice that of placebo) were insomnia (2%), increased blood pressure (2%), decreased appetite (1%), and headache (1%).
PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Controlled Substance Status/High Potential for Abuse and Dependence
- Advise patients and their caregivers that Mydayis is a federally controlled substance because it can be abused or lead to dependence. Advise patients to store Mydayis in a safe place, preferably locked, to prevent abuse. Advise patients to comply with laws and regulations on drug disposal. Advise patients to dispose of remaining, unused, or expired Mydayis by a medicine take-back program if available.
Serious Cardiovascular Risks
- Advise patients, caregivers, and family members that there is a potential serious cardiovascular risk including sudden death, myocardial infarction, stroke, and hypertension, with Mydayis use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease.
Blood Pressure and Heart Rate Increases
- Instruct patients that Mydayis can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects.
- Advise patients that Mydayis, at recommended doses, may cause psychotic or manic symptoms, even in patients without prior history of psychotic symptoms or mania.
Long-Term Suppression of Growth
- Advise patients, family members, and caregivers that amphetamines may cause slowing of growth, including weight loss.
Circulation Problems in Fingers and Toes (Peripheral Vasculopathy, Including Raynaud’s Phenomenon)
- Instruct patients beginning treatment with Mydayis about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change from pale, to blue, to red. Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes. Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking Mydayis. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.
- Caution patients that Mydayis may lower the convulsive threshold. Advise patients to contact their healthcare provider immediately and to discontinue Mydayis if a seizure occurs.
- Caution patients about the risk of serotonin syndrome with concomitant use of Mydayis and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid). Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.
- Advise patients to notify their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs because there is a potential for interactions.
- Advise patients of the potential fetal effects from the use of Mydayis during pregnancy. Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with Mydayis.
- There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Mydayis during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/.
- Advise women not to breastfeed if they are taking Mydayis.
- Advise patients to avoid alcohol while taking Mydayis. Consumption of alcohol while taking Mydayis may result in a more rapid release of the dose of mixed amphetamine salts.
This patient counseling information does not include all the information needed to use Mydayis. See Full Prescribing Information.
- Mydayis [package insert]. Lexington, MA; Takeda US Inc.
- Brams M, Childress AC, Greenbaum M, et al. SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: results of a randomized, double-blind, placebo-controlled study. J Child Adolesc Psychopharmacol. 2017. doi:10.1089/cap.2017.0053.
- Data on file; SPD465-305; Shire US Inc.